VERTEX PHARMACEUTICALS INC / MA Payments to Acquire Investments
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Payments to Acquire Investments of $27.22 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2019-10-31
- VERTEX PHARMACEUTICALS INC / MA payments to acquire investments for the quarter ending 2019-09-30 was $7.22M, a 81.48% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire investments for the quarter ending 2019-06-30 was $20.00M.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire investments for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire investments for the quarter ending 2018-09-30 was $38.99M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month |
|---|---|---|---|
| 2019-09-30 | $7.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $27.22M derived: sum of 2 quarters · filed 2019-10-31 | $27.22M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $20.00M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | ||
| 2018-09-30 | $38.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $38.99M derived: sum of 2 quarters · filed 2019-10-31 | $60.49M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $21.50M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $21.50M 10-Q · filed 2019-05-01 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2018-10-25 | $0.00 10-Q · filed 2018-10-25 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-04-27 | ||
| 2016-09-30 | $23.07M 10-Q · filed 2017-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |